Welcome to our dedicated page for Swk Hldgs SEC filings (Ticker: SWKH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the numbers behind SWK Holdings’ royalty-backed loans or Enteris BioPharma milestones? Investors typically open a filing to track how much cash those life-science royalties generate, whether credit-quality on finance receivables is shifting, and when executives buy or sell shares. That information lives deep inside the SWK Holdings annual report 10-K, every SWK Holdings quarterly earnings report 10-Q filing, and a steady stream of 8-Ks.
Stock Titan’s AI platform turns that search into a two-minute task. Type a natural question—“understanding SWK Holdings SEC documents with AI” or “SWK Holdings insider trading Form 4 transactions”—and receive an instant summary that pinpoints royalty income tables, allowance for credit losses, and segment results. Real-time alerts flag SWK Holdings Form 4 insider transactions as soon as they reach EDGAR, while our side-by-side redlines highlight material changes between periods.
You’ll also find:
- 8-K material events explained in plain English, so you can gauge new loan originations or Enteris partnership updates without dissecting legal language.
- Proxy statement executive compensation breakdowns that link pay to portfolio performance.
- Concise tables comparing revenue‐share percentages across each financed asset—critical for anyone performing a SWK Holdings earnings report filing analysis.
Whether you need a quick view of SWK Holdings executive stock transactions Form 4 or a deeper dive into credit‐risk footnotes, our comprehensive archive and AI-powered summaries keep every SEC filing explained simply—no spreadsheet sprawl, no jargon chase.
SWK Holdings Corp director Robert K. Hatcher acquired 3,858 shares of common stock at $14.26 per share on June 16, 2025, increasing his direct holdings to 16,662 shares.
Key transaction details:
- The shares were issued as part of director compensation, with Hatcher electing to receive stock instead of cash payment
- The restricted shares have a vesting schedule, maturing on the earlier of June 16, 2026, or the next Annual Meeting of Stockholders
- Vesting is contingent on Hatcher's continued service as director
- The transaction was reported within the required filing window on June 18, 2025
This insider transaction demonstrates director alignment with shareholder interests through equity-based compensation, with Hatcher voluntarily choosing stock over cash payment for his board service.
Director Jerry Albright of SWK Holdings (SWKH) acquired 3,858 shares of common stock on June 16, 2025, at a price of $14.26 per share. Following this transaction, Albright's direct ownership increased to 10,832 shares.
Key transaction details:
- The shares were issued as part of director compensation, with Albright electing to receive stock instead of cash payment
- The restricted shares are subject to a vesting schedule, maturing on the earlier of:
- June 16, 2026
- The next Annual Meeting of Stockholders
- Vesting is contingent on Albright's continued service as director
This insider transaction demonstrates director alignment with shareholder interests through equity-based compensation.
FAQ
What is the current stock price of Swk Hldgs (SWKH)?
What is the market cap of Swk Hldgs (SWKH)?
What is the primary business of SWK Holdings Corp?
How does SWK generate its revenue?
What are the core operating segments of SWK Holdings?
How does SWK support life science companies?
What role does Enteris BioPharma play within the company?
What financing structures does SWK employ?
Who are the typical clients of SWK Holdings?
What differentiates SWK Holdings from other financing providers in the market?
